Royal Philips, a global leader in health technology, has secured the top position in medical technology in the European Patent Office’s (EPO) 2025 Technology Dashboard. The ranking highlights the company’s continued leadership in healthcare innovation.
In 2025, Philips filed 676 medical technology patent applications with the EPO, including a significant number focused on artificial intelligence (AI). This reflects the company’s strong innovation pipeline centered on data-driven and platform-based health solutions.
Marnix van Ginneken, Member of the Board of Management at Royal Philips, emphasized that the company’s success as a leading EPO applicant demonstrates the strength of its innovation engine and its commitment to meaningful innovation in healthcare and self-care. He noted that Philips’ strategy is powered by data, AI, and platform-based solutions to deliver better care to more people.
Philips’ innovations improved the lives of 2 billion people in 2025. The company aims to reach 2.5 billion people annually by 2030, including 400 million individuals in underserved communities.
Recent innovations from Philips include:
- Helium-free 3.0T MRI technology, enabling more sustainable and precise diagnostic imaging.
- Verida spectral CT system and Rembra CT, delivering faster and more accurate diagnostic insights.
- LumiGuide 3D Device Guidance, the first real-time, AI-enabled light-based 3D navigation solution for image-guided therapy.
- ECG AI Marketplace, providing cardiac care teams with access to multiple AI-powered diagnostic tools.
- Consumer innovations such as the AI-powered i9000 Shaver Series, Philips Lumea IPL, and the Avent Hands-Free Breast Pump.
Overall, Philips submitted 1,289 European patent applications across multiple domains, maintaining its position as the largest Dutch applicant. The company was also named a Clarivate Top 100 Global Innovator for the 13th consecutive year and invested over 9% of its revenue in R&D in 2025, setting a benchmark in the industry.
